Premium
Vertex Pharmac Dl 01 (1VRTX)
BIT
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -828,00 | 364,25k | Automatic Disposition | 439,91 | 19,96k | -3,98% |
| 2026-05-29 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1,97k | 888,30k | Automatic Disposition | 450,00 | 22,76k | -7,98% |
| 2026-05-15 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -33,00 | 14,96k | Automatic Disposition | 453,45 | 7,28k | -0,45% |
| 2026-05-15 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1,35k | 613,97k | Automatic Disposition | 453,45 | 24,73k | -5,19% |
| 2026-05-12 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -6,99k | 3,14M | Automatic Disposition | 450,00 | 26,09k | -21,13% |
| 2026-05-01 | Mr. Suketu P. UpadhyayInitié | -796,00 | 0,00 | Sale to Issuer | - | 1,56k | -33,81% |
| 2026-05-01 | Ms. Nancy A. ThornberryIndependent Director | -398,00 | 0,00 | Sale to Issuer | - | 1,64k | -19,56% |
| 2026-05-01 | Dr. Jennifer SchneiderIndependent Director | -796,00 | 0,00 | Sale to Issuer | - | 922,00 | -46,33% |
| 2026-05-01 | Ms. Diana Lynne McKenzieIndependent Director | -796,00 | 0,00 | Sale to Issuer | - | 1,64k | -32,65% |
| 2026-05-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -1,10k | 469,22k | Automatic Disposition | 425,02 | 20,73k | -5,06% |
| 2026-05-04 | Dr. Sangeeta N. BhatiaIndependent Director | -318,00 | 134,75k | Vente | 423,73 | 3,98k | -7,40% |
| 2026-04-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -978,00 | 439,29k | Automatic Disposition | 449,17 | 21,83k | -4,29% |
| 2026-03-27 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2,33k | 1,05M | Automatic Disposition | 450,95 | 33,08k | -6,58% |
| 2026-03-13 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2,33k | 1,12M | Automatic Disposition | 481,79 | 35,41k | -6,17% |
| 2026-03-11 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2,63k | 1,31M | Automatic Disposition | 498,42 | 12,49k | -17,41% |
| 2026-03-04 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2,44k | 1,16M | Automatic Disposition | 475,30 | 15,12k | -13,88% |
| 2026-03-02 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -892,00 | 442,40k | Automatic Disposition | 495,96 | 22,81k | -3,76% |
| 2026-02-27 | Dr. Reshma KewalramaniCEO, President & Director | -40,00k | 19,74M | Automatic Disposition | 479,75 - 496,95 | 98,28k | -28,93% |
| 2026-02-27 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2,33k | 1,12M | Automatic Disposition | 480,31 | 37,73k | -5,81% |
| 2026-02-26 | Ms. Kristen C. AmbroseSenior VP & CAO | -357,00 | 172,56k | Automatic Disposition | 483,36 | 6,62k | -5,11% |
| 2026-02-24 | Mr. Charles F. WagnerExec. VP, COO & CFO | -1,74k | 846,03k | Sale to Issuer | 485,11 | 27,72k | -5,92% |
| 2026-02-25 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -260,00 | 126,45k | Automatic Disposition | 486,35 | 29,50k | -0,87% |
| 2026-02-24 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -1,63k | 789,27k | Sale to Issuer | 485,11 | 29,50k | -5,23% |
| 2026-02-25 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -1,85k | 897,80k | Automatic Disposition | 486,35 | 65,75k | -2,73% |
| 2026-02-24 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -1,52k | 736,40k | Sale to Issuer | 485,11 | 65,75k | -2,26% |
| 2026-02-25 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -4,91k | 2,39M | Automatic Disposition | 486,35 - 489,00 | 17,56k | -21,85% |
| 2026-02-24 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -873,00 | 423,50k | Sale to Issuer | 485,11 | 17,56k | -4,74% |
| 2026-02-24 | Dr. Jeffrey Marc LeidenExecutive Chairman | -3,55k | 1,72M | Sale to Issuer | 485,11 | 35,24k | -9,15% |
| 2026-02-24 | Dr. Reshma KewalramaniCEO, President & Director | -4,98k | 2,42M | Sale to Issuer | 485,11 | 94,58k | -5,00% |
| 2026-02-25 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -620,00 | 301,54k | Automatic Disposition | 486,35 | 7,28k | -7,84% |
| 2026-02-24 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -582,00 | 282,33k | Sale to Issuer | 485,11 | 7,28k | -7,40% |
| 2026-02-24 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1,45k | 704,86k | Sale to Issuer | 485,11 | 40,06k | -3,50% |
| 2026-02-25 | Mr. Jonathan BillerInitié | -945,00 | 459,60k | Automatic Disposition | 486,35 | 13,66k | -6,47% |
| 2026-02-24 | Mr. Jonathan BillerInitié | -1,14k | 554,97k | Sale to Issuer | 485,11 | 13,66k | -7,73% |
| 2026-02-25 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -668,00 | 324,88k | Automatic Disposition | 486,35 | 18,43k | -3,50% |
| 2026-02-24 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1,63k | 789,27k | Sale to Issuer | 485,11 | 18,43k | -8,11% |
| 2026-02-25 | Ms. Kristen C. AmbroseSenior VP & CAO | -223,00 | 108,46k | Automatic Disposition | 486,35 | 6,98k | -3,10% |
| 2026-02-24 | Ms. Kristen C. AmbroseSenior VP & CAO | -546,00 | 264,87k | Sale to Issuer | 485,11 | 6,98k | -7,25% |
| 2026-02-19 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -48,51k | 14,37M | Derivative Exercise and Sale | 155,57 - 470,54 | 69,12k | - |
| 2026-02-19 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -10,11k | 4,76M | Automatic Disposition | 470,54 - 471,43 | 69,12k | -12,76% |
| 2026-02-17 | Mr. Charles F. WagnerExec. VP, COO & CFO | -2,29k | 1,11M | Sale to Issuer | 483,75 | 23,49k | -8,90% |
| 2026-02-17 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -977,00 | 472,40k | Automatic Disposition | 473,68 - 489,46 | 28,02k | -3,37% |
| 2026-02-17 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -2,29k | 1,11M | Sale to Issuer | 483,75 | 28,02k | -7,57% |
| 2026-02-17 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -2,14k | 1,04M | Sale to Issuer | 483,75 | 79,23k | -2,63% |
| 2026-02-17 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -1,15k | 555,35k | Sale to Issuer | 483,75 | 23,34k | -4,69% |
| 2026-02-18 | Dr. Jeffrey Marc LeidenExecutive Chairman | -2,96k | 1,43M | Sale to Issuer | 483,75 | 29,77k | -9,05% |
| 2026-02-17 | Dr. Reshma KewalramaniCEO, President & Director | -6,55k | 3,17M | Sale to Issuer | 483,75 | 89,26k | -6,84% |
| 2026-02-17 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -3,62k | 1,75M | Automatic Disposition | 473,68 - 489,46 | 8,49k | -29,90% |
| 2026-02-17 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -1,11k | 536,96k | Sale to Issuer | 483,75 | 8,49k | -11,57% |
| 2026-02-17 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1,91k | 924,93k | Sale to Issuer | 483,75 | 41,52k | -4,40% |
| 2026-02-17 | Mr. Jonathan BillerInitié | -3,72k | 1,80M | Automatic Disposition | 473,68 - 489,46 | 15,75k | -19,11% |
| 2026-02-17 | Mr. Jonathan BillerInitié | -1,51k | 728,04k | Sale to Issuer | 483,75 | 15,75k | -8,72% |
| 2026-02-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -2,85k | 1,38M | Automatic Disposition | 473,68 - 489,46 | 20,73k | -12,08% |
| 2026-02-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1,53k | 740,14k | Sale to Issuer | 483,75 | 20,73k | -6,87% |
| 2026-02-17 | Ms. Kristen C. AmbroseSenior VP & CAO | -2,20k | 1,06M | Automatic Disposition | 473,68 - 489,46 | 7,75k | -22,07% |
| 2026-02-17 | Ms. Kristen C. AmbroseSenior VP & CAO | -598,00 | 289,28k | Sale to Issuer | 483,75 | 7,75k | -7,16% |
| 2026-02-13 | Mr. Charles F. WagnerExec. VP, COO & CFO | -4,57k | 2,23M | Sale to Issuer | 487,76 | 23,42k | -16,32% |
| 2026-02-13 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -1,50k | 749,99k | Automatic Disposition | 499,99 | 26,55k | -5,35% |
| 2026-02-13 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -3,80k | 1,86M | Sale to Issuer | 487,76 | 26,55k | -12,53% |
| 2026-02-13 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -3,55k | 1,73M | Sale to Issuer | 487,76 | 75,58k | -4,48% |
| 2026-02-13 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2,28k | 1,11M | Sale to Issuer | 487,76 | 19,53k | -10,47% |
| 2026-02-13 | Dr. Reshma KewalramaniCEO, President & Director | -13,04k | 6,36M | Sale to Issuer | 487,76 | 133,49k | -8,90% |
| 2026-02-13 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -2,28k | 1,11M | Sale to Issuer | 487,76 | 10,63k | -17,68% |
| 2026-02-13 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -3,80k | 1,86M | Sale to Issuer | 487,76 | 38,05k | -9,09% |
| 2026-02-13 | Mr. Jonathan BillerInitié | -988,00 | 493,01k | Automatic Disposition | 499,00 | 16,84k | -5,54% |
| 2026-02-13 | Mr. Jonathan BillerInitié | -2,99k | 1,46M | Sale to Issuer | 487,76 | 16,84k | -15,09% |
| 2026-02-13 | Dr. Sangeeta N. BhatiaIndependent Director | -266,00 | 133,00k | Automatic Disposition | 500,00 | 3,50k | -7,06% |
| 2026-02-13 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1,90k | 928,21k | Sale to Issuer | 487,76 | 20,14k | -8,63% |
| 2026-02-13 | Ms. Kristen C. AmbroseSenior VP & CAO | -1,39k | 679,45k | Sale to Issuer | 487,76 | 8,73k | -13,76% |
| 2026-02-10 | Mr. Charles F. WagnerExec. VP, COO & CFO | -3,05k | 1,43M | Sale to Issuer | 468,41 | 18,54k | -14,11% |
| 2026-02-11 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -466,00 | 214,56k | Automatic Disposition | 460,43 | 23,99k | -1,91% |
| 2026-02-10 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -2,14k | 1,00M | Sale to Issuer | 468,41 | 23,99k | -8,19% |
| 2026-02-10 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -2,06k | 963,52k | Sale to Issuer | 468,41 | 79,12k | -2,53% |
| 2026-02-10 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -1,13k | 527,90k | Sale to Issuer | 468,41 | 21,81k | -4,91% |
| 2026-02-10 | Dr. Reshma KewalramaniCEO, President & Director | -8,30k | 3,89M | Sale to Issuer | 468,41 | 146,53k | -5,36% |
| 2026-02-11 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -2,02k | 930,53k | Automatic Disposition | 460,43 | 12,91k | -13,53% |
| 2026-02-10 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -1,13k | 527,90k | Sale to Issuer | 468,41 | 12,91k | -8,03% |
| 2026-02-10 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2,15k | 1,00M | Sale to Issuer | 468,41 | 41,86k | -4,87% |
| 2026-02-11 | Mr. Jonathan BillerInitié | -1,93k | 886,33k | Automatic Disposition | 460,43 | 20,82k | -8,46% |
| 2026-02-10 | Mr. Jonathan BillerInitié | -1,63k | 763,51k | Sale to Issuer | 468,41 | 20,82k | -7,26% |
| 2026-02-11 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1,75k | 806,21k | Automatic Disposition | 460,43 | 22,05k | -7,36% |
| 2026-02-10 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -872,00 | 408,45k | Sale to Issuer | 468,41 | 22,05k | -3,80% |
| 2026-02-11 | Ms. Kristen C. AmbroseSenior VP & CAO | -1,38k | 633,55k | Automatic Disposition | 460,43 | 10,13k | -11,96% |
| 2026-02-10 | Ms. Kristen C. AmbroseSenior VP & CAO | -592,00 | 277,30k | Sale to Issuer | 468,41 | 10,13k | -5,52% |
| 2026-01-07 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -4,50k | 2,14M | Automatic Disposition | 474,99 | 21,35k | -17,41% |
| 2026-01-06 | Mr. Charles F. WagnerExec. VP, COO & CFO | -9,53k | 2,59M | Derivative Exercise and Sale | 189,38 - 461,00 | 15,29k | - |
| 2025-12-03 | Mr. Charles F. WagnerExec. VP, COO & CFO | -14,00k | 6,38M | Automatic Disposition | 451,00 - 461,00 | 15,29k | -47,80% |
| 2025-12-03 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -4,50k | 2,02M | Automatic Disposition | 449,99 | 25,85k | -14,83% |
| 2025-12-04 | Dr. Jeffrey Marc LeidenExecutive Chairman | 1,00 | 91,05 | Derivative Exercise and Retained Stock | 91,05 | 24,47k | 0,00% |
| 2025-12-03 | Dr. Jeffrey Marc LeidenExecutive Chairman | -63,78k | 23,13M | Derivative Exercise and Sale | 86,52 - 455,22 | 24,47k | - |
| 2025-12-03 | Mr. Jonathan BillerInitié | -347,00 | 155,80k | Automatic Disposition | 449,00 | 15,31k | -2,22% |
| 2025-11-19 | Mr. Lloyd A. CarneyIndependent Director | -800,00 | 0,00 | Other Disposition | - | 5,52k | -12,66% |
| 2025-11-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -2,50k | 1,09M | Automatic Disposition | 434,58 | 16,85k | -12,92% |
| 2025-11-13 | Dr. Jeffrey Marc LeidenExecutive Chairman | -73,29k | 25,80M | Derivative Exercise and Sale | 86,52 - 442,00 | 24,47k | - |
| 2025-10-02 | Mr. Jonathan BillerInitié | -694,00 | 280,52k | Automatic Disposition | 404,21 | 15,65k | -4,25% |
| 2025-10-01 | Mr. Jonathan BillerInitié | -1,26k | 503,60k | Sale to Issuer | 400,00 | 15,65k | -7,44% |
| 2025-08-27 | Dr. Sangeeta N. BhatiaIndependent Director | -266,00 | 102,86k | Automatic Disposition | 386,69 | 3,77k | -6,59% |
| 2025-08-06 | Dr. Reshma KewalramaniCEO, President & Director | 10,00k | 3,90M | Achat | 389,08 - 389,95 | 115,97k | 9,44% |
| 2025-08-06 | Mr. Bruce I. SachsLead Independent Director | 5,00k | 1,95M | Achat | 389,36 - 389,84 | 45,00k | 12,50% |
| 2025-07-01 | Mr. Stuart A. ArbuckleInitié | -37,24k | 16,77M | Sale to Issuer | 450,23 | 63,51k | -36,97% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
